Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Venous thromboembolism diagnosed incident cases to reach 1.71 million across 7MM in 2034, forecasts GlobalData

The burden of diagnosed incident cases of venous thromboembolism (VTE) in the seven major markets (7MM*) is expected to increase at an annual growth rate (AGR) of 1.41% from 1.5 million in 2024 to 1.71 million cases in 2034, forecasts GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Venous Thromboembolism: Epidemiology Forecast to […]
Read more

Pharma firms accelerate regional capacity building to secure GLP-1 supply and mitigate geopolitical risks, reveals GlobalData

Regionalized glucagon-like peptide-1 (GLP-1) manufacturing investments and rising Middle East geopolitical disruptions are reshaping pharmaceutical supply strategies, pushing drugmakers to localize production, secure inventories, and build resilient Asia-focused capacity. The shift reflects intensifying demand for metabolic therapies and growing logistics risk, signaling a structural move toward geographically diversified manufacturing networks to protect launches, stabilize supply, […]
Read more

FDA-approved drug manufacturing deals shift to Europe, says GlobalData

In 2025, US contract manufacturing deals for FDA-approved drugs posted their steepest decline in five years. Despite record-high US tariffs on EU pharmaceuticals, biopharma companies, including US-based firms, are increasingly choosing to outsource manufacturing for the US market to facilities in Europe rather than shifting work to domestic providers, according to GlobalData, a leading intelligence […]
Read more

Biopharma catalysts in Q2 2026 signal high-profile approval decisions and rising competition, reveals GlobalData

An unclear outlook for Replimune’s BLA resubmission outlook for vusolimogene oderparepvec in advanced melanoma and debated clinical positioning for Arvinas’s vepdegestrant and Boehringer Ingelheim’s survodutide underscore intensifying competition across breast cancer and obesity therapeutics among other major catalysts are expected in Q2 2026, according to GlobalData, a leading intelligence and productivity platform. The FDA’s initial rejection […]
Read more

Longer-term real-world data needed to compare Leqembi and Kisunla opposing treatment strategies for Alzheimer’s, says GlobalData

In the current Alzheimer’s disease (AD) therapeutic space, the two approved disease-modifying therapies (DMTs) employ different treatment strategies, although both are anti-amyloid-beta (Aβ) monoclonal antibodies (mAbs). Eisai/Biogen’s Leqembi (lecanemab) is approved for continuous treatment until progression to moderate AD, whereas Eli Lilly’s Kisunla (donanemab) is being positioned as a finite treatment option that can be […]
Read more

Parkinson’s Awareness Month 2026: Alpha synuclein emerges as leading target in disease pipeline, says GlobalData

As Parkinson’s disease (PD) awareness month approaches this April, analysis of the global drug landscape reveals an evolving research focus in PD. While pharmaceutical research has historically concentrated on dopamine signaling, the current pipeline indicates increased interest in alpha synuclein as a therapeutic target, according to GlobalData, a leading intelligence and productivity platform. Most current […]
Read more

Late-stage pipeline to transform progressive pulmonary fibrosis treatment landscape, says GlobalData

Progressive pulmonary fibrosis (PPF) describes a phenotype of non-idiopathic pulmonary fibrosis (IPF) interstitial lung diseases (ILDs) that continues to worsen despite appropriate management, leading to lung scarring, loss of lung function, and early mortality. Current antifibrotic agents slow the rate of forced vital capacity (FVC) decline but do not halt or reverse fibrosis, leaving substantial […]
Read more

Sasineprocel’s future lies as a monotherapy in Parkinson’s disease, says GlobalData

Sasineprocel’s encouraging Phase I/IIa data positions autologous iPSC-derived dopaminergic neuron therapy as a potential monotherapy challenger in Parkinson’s disease (PD), signaling a shift toward regenerative treatment strategies beyond symptomatic dopamine replacement. Strong safety, graft survival, and functional improvements underscore its disruptive promise, though cost, reimbursement hurdles, and upcoming Phase III validation will determine its real-world […]
Read more

IRLAB’s Phase IIb pirepemat data highlights opportunity in Parkinson’s disease falls management, says GlobalData

Integrative Research Laboratories Sweden AB’s (IRLAB) Phase IIb REACT-PD trial results for pirepemat highlight both the promise and the complexity of targeting non-dopaminergic symptoms in Parkinson’s disease (PD), particularly falls and balance impairment, which remain major unmet needs, says GlobalData, a leading intelligence and productivity platform. Presented at the AD/PD 2026 International Conference, the REACT-PD […]
Read more

Ecnoglutide approval intensifies competition in China GLP-1 obesity market, says GlobalData

China’s approval of Sciwind Biosciences’ Ecnoglutide injection as the fifth GLP-1 obesity therapy signals intensifying competition in one of the world’s fastest-growing metabolic drug markets. Strong Phase III efficacy and a landmark commercialization partnership with Pfizer highlight rising strategic interest in obesity treatments, positioning China as a key battleground for innovation, pricing competition, and global […]
Read more

Proposed US childhood vaccine cuts threaten domestic manufacturing demand, says GlobalData

Proposed cuts to the US childhood immunization schedule and weakening state-level vaccine mandates threaten to erode domestic vaccine demand, placing pressure on the country’s manufacturing base. As the industry already adjusts to the post-COVID-19 normalization of vaccine demand, declining vaccination rates and policy shifts risk undermining production volumes, sales prospects, and long-term investment incentives for […]
Read more

TrumpRx and Medicare highlight shifting pharma industry priorities, says GlobalData

The US administration’s TrumpRx initiative and a proposed Medicare incentive rule link drug pricing, tariff policy, and domestic manufacturing in a coordinated push to reshore pharmaceutical production, highlighting shifting industry priorities, says GlobalData, a leading intelligence and productivity platform. Launched in February 2026, TrumpRx enables cash-paying and uninsured patients to access selected branded medicines at […]
Read more

Model Medicines’ MDL-001 holds potential to strengthen pandemic preparedness across multiple infectious diseases, says GlobalData

Model Medicines presented an update on its lead candidate MDL-001 at the Biocom Global Partnering Conference in California, positioning the asset as a first-in-class oral direct-acting antiviral with demonstrated preclinical activity across various viral families, including respiratory, hepatic, and gastrointestinal viruses. With such a broad therapeutic spectrum, MDL-001 has potential to address unmet needs including […]
Read more

Shifting operating landscape for pharma and biotech: Join GlobalData’s webinar for 2026 outlook

Mounting geopolitical tensions, evolving trade policies, regulatory reform, and structural changes in global health financing are reshaping the operating environment for pharmaceutical and biotech companies. Against this complex backdrop, growth expectations for healthcare spending and pharmaceutical sales are being recalibrated across major markets, says GlobalData, a leading intelligence and productivity platform. To assess these developments, […]
Read more

 argenX’s Vyvgart holds potential to break into ocular myasthenia gravis market, says GlobalData

argenX recently announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the phase III Adapt Oculus study. The study evaluated the efficacy and safety of Vyvgart administered by prefilled syringe in adult patients with ocular MG (MGFA Class I) who are acetylcholine receptor antibody–positive (AChR+). The results demonstrate Vyvgart’s potential for early […]
Read more

Merck’s DOR/ISL will compete with standard of care as a 2-drug STR, says GlobalData

A Phase III switch study occurring over 96 weeks has demonstrated that Merck’s doravirine/islatravir (DOR/ISL) sustains durable viral suppression with stable safety outcomes in virologically suppressed adults with HIV, reinforcing momentum behind two-drug single-tablet regimens (STR). The data positions DOR/ISL as a credible integrase-sparing challenger in a market recalibrating toward simplified, lower-toxicity maintenance strategies ahead […]
Read more

Unmet needs remain substantial in progressive pulmonary fibrosis, says GlobalData

Progressive pulmonary fibrosis (PPF) represents one of the most challenging phenotypes within the interstitial lung disease (ILD) space and is defined by worsening fibrosis observed by high-resolution computed tomography scans, declining lung function, and persistent symptoms. Although the approval of antifibrotics have expanded treatment options in recent years, they primarily slow functional decline rather than […]
Read more

Knight’s axatilimab regulatory submission in Brazil indicates growth in GvHD therapeutics, says GlobalData

Knight Therapeutics’ regulatory submission of Niktimvo (axatilimab) in Brazil marks an important milestone in expanding access to novel therapies for chronic graft-versus-host disease (cGvHD) across Latin America. The filing reflects growing regional momentum in advanced immunology and transplant-related therapies, highlighting Brazil’s strategic importance as a key pharmaceutical market in the region, says GlobalData, a leading […]
Read more

AbbVie’s $100 billion US deal and FDA reforms highlight growing focus on domestic manufacturing, says GlobalData

AbbVie’s $100 billion agreement with the US administration signals a structural recalibration of drug pricing negotiations, tying tariff exemptions and pricing flexibility directly to domestic manufacturing expansion. Coupled with the evolving US Food and Drug Administration manufacturing reforms, the deal underscores a policy-driven shift that embeds capital investment, supply chain resilience, and advanced biologics capacity […]
Read more

Huayunuo approval positions China at forefront of viral hepatitis innovation, says GlobalData

Huahui Health has recently secured conditional approval from China’s National Medical Products Administration (NMPA) for Huayunuo (Libevitug Injection), marking it as the first domestically developed monoclonal antibody (mAb) drug for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. This move not only addresses a critical treatment gap but also signals China’s […]
Read more
1 2 3 4 5 … 108